Intranasal olanzapine formulations and methods of their use
Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.
1. A composition comprising:
about 1% w/v to about 15% w/v of olanzapine or a pharmaceutically acceptable salt thereof;
about 0.1% w/v to about 1% w/v of dodecyl maltoside;
about 30% w/v to about 40% w/v of N,N-dimethylacetamide; and
about 40% w/v to about 70% w/v of polyethylene glycol, wherein the composition is a non-aqueous solution comprising less than about 3% w/v of water.
2. The composition of claim 1 , comprising about 2.5% w/v to about 12% w/v of the olanzapine or a pharmaceutically acceptable salt thereof.
3. The composition of claim 1 , comprising about 0.20% w/v to about 0.50% w/v of the dodecyl maltoside.
4. The composition of claim 1 , comprising about 34% w/v to about 38% w/v of the N,N-dimethylacetamide.
5. The composition of claim 1 , wherein the polyethylene glycol has an average molecular weight of about 200 Da to about 1000 Da.
6. The composition of claim 1 , wherein the polyethylene glycol has an average molecular weight of about 600 Da.
7. The composition of claim 1 , comprising about 44% w/v to about 66% w/v of the polyethylene glycol.
8. The composition of claim 1 , wherein the amount of olanzapine is about 1 mg to about 15 mg or a pharmaceutically acceptable salt thereof.
9. The composition of claim 1 , wherein the ratio of the polyethylene glycol to the N,N-dimethylacetamide is from about 4:1 to about 1:4.
10. The composition of claim 1 , wherein the ratio of the polyethylene glycol to the N,N-dimethylacetamide is about 3:2.
11. The composition of claim 1 , comprising about 2.5% w/v to about 12% w/v of the olanzapine or a pharmaceutically acceptable salt thereof, about 0.20% w/v to about 0.50% w/v of the dodecyl maltoside, about 34% w/v to about 38% w/v of the N,N-dimethylacetamide, and about 44% w/v to about 66% w/v of the polyethylene glycol.
12. The composition of claim 1 , wherein the composition comprises less than 1% w/v of water.
13. The composition of claim 1 , wherein the composition comprises less than about 0.1% w/v of water.
14. A single-use spray device comprising the composition according to claim 1 , configured to discharge a volume of the composition that corresponds to 2.5 mg olanzapine to 15 mg of olanzapine upon actuation of the device.
15. A method of treating acute agitation associated with one or more of schizophrenia, schizoaffective disorder, and bipolar disorder in a subject in need thereof comprising intranasally administering a composition comprising about 1% w/v to about 15% w/v of olanzapine or a pharmaceutically acceptable salt thereof, about 0.1% w/v to about 1% w/v dodecyl maltoside, about 30% w/v to about 40% w/v N,N-dimethylacetamide, and about 40% w/v to about 70% w/v of polyethylene glycol to a nasal mucosal membrane of the subject, wherein the composition is a non-aqueous solution comprising less than about 3% w/v of water.
16. The method of claim 15 , wherein the composition comprises about 1 mg to about 15 mg of the olanzapine or a pharmaceutically acceptable salt thereof.
17. The method of claim 15 , wherein the composition comprises about 2.5 mg to about 10 mg of the olanzapine or a pharmaceutically acceptable salt thereof.
18. The method of claim 15 , wherein the composition comprises about 0.20 mg to about 0.50 mg of the dodecyl maltoside.
19. The method of claim 15 , wherein the composition comprises about 34% w/v to about 38% w/v of the N,N-dimethylacetamide.
20. The method of claim 15 , wherein the polyethylene glycol has an average molecular weight of about 200 Da to about 1000 Da.
21. The method of claim 15 , wherein the composition comprises about 44% w/v to about 66% w/v of the polyethylene glycol.
22. The method of claim 15 , wherein the ratio of the polyethylene glycol to the N,N-dimethylacetamide is from about 4:1 to about 1:4.
23. The method of claim 15 , wherein the ratio of the polyethylene glycol to the N,N-dimethylacetamide is about 3:2.
24. The method of claim 15 , wherein the composition comprises about 2.5 mg to about 15 mg of the olanzapine or a pharmaceutically acceptable salt thereof, about 0.20% w/v to about 0.50% w/v dodecyl maltoside, about 34% w/v to about 38% w/v of the N,N-dimethylacetamide, and about 44% w/v to about 66% w/v of polyethylene glycol.
25. The method of claim 15 , wherein the severity of the acute agitation in the subject is reduced within about 20 minutes after administration.
26. The method of claim 15 , wherein the composition is provided in a pre-primed single use dosing device containing about 75 μL to about 200 μL of the composition.
27. The method of claim 15 , wherein the composition is provided in a pre-primed single use dosing device containing about 100 μL of the composition.
28. The method of claim 15 , wherein said administering comprises administering about 75 μL to about 200 μL of the composition to each nostril of the subject.
29. The method of claim 15 , wherein said administering comprises administering about 100 μL of the composition to each nostril of the subject.
30. The method of claim 15 , wherein the composition comprises less than 1% w/v of water.